CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 605 enrolled
Drug / intervention
Ferumoxytol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01114204
NCT01114204Phase 3Completed

A Phase III, Randomized, Open-label, Active-Controlled, Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency Anemia

AMAG Pharmaceuticals, Inc.·interventional·Posted May 3, 2010·Updated Apr 21, 2022

In Brief

A Phase 3 clinical trial evaluating Ferumoxytol and Iron Sucrose for Iron Deficiency Anemia. Completed, enrolled 605 participants across 96 sites in 14 countries.

Detailed Summary

The purpose of the study is to evaluate the efficacy and safety of intravenous (IV) ferumoxytol compared to IV iron sucrose for the treatment of iron deficiency anemia (IDA).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, France, Germany, Hungary, Italy, Latvia, Lithuania, Poland, Romania, South Africa, South Korea, Spain, Ukraine, United Kingdom
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 3, 2010
Enrollment StartAug 10, 2010
Primary CompletionNov 9, 2011
Study CompletionJun 25, 2012
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 16.2 years ago

Interventions

Ferumoxytoldrug

IV Ferumoxytol

Iron Sucrosedrug

IV Iron Sucrose